Welcome to our dedicated page for TREVENA news (Ticker: TRVN), a resource for investors and traders seeking the latest updates and insights on TREVENA stock.
Trevena, Inc. (Nasdaq: TRVN) is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies targeting G protein-coupled receptors (GPCRs). The company's mission is to improve patient outcomes and reduce healthcare costs through novel therapies. Trevena's pipeline includes four key drug candidates:
- TRV130 (OLINVYK®): An FDA-designated breakthrough therapy for the intravenous treatment of acute moderate to severe pain, currently in Phase 3 testing. Recently, OLINVYK's effectiveness was assessed in the VOLITION study, showing promising results in terms of respiratory, gastrointestinal, and cognitive function outcomes in postoperative settings.
- TRV027: Evaluated in a Phase 2b study for treating acute heart failure, this candidate aims to address unmet needs in cardiovascular treatment.
- TRV734: Completed Phase 1 testing for the oral treatment of acute and chronic pain, TRV734 seeks to provide a non-opioid alternative for pain management.
- TRV250: In preclinical development for migraine treatment, focusing on innovative solutions for CNS disorders.
Trevena's pipeline is based on Nobel Prize-winning research, emphasizing its commitment to pioneering medical advancements. The company has collaborations with prominent institutions like Wake Forest Baptist Health and the Cleveland Clinic, ensuring rigorous evaluation and development of its therapies. Trevena is also exploring TRV045 for diabetic neuropathic pain and epilepsy, showcasing the potential impact beyond pain management.
Financially, Trevena has shown resilience, recently reporting a net loss reduction and strengthening its balance sheet with significant capital injections. The company continues to focus on strategic partnerships and innovative research to maintain its competitive edge in the biopharmaceutical industry.
For more information, please visit www.Trevena.com.
Trevena, Inc. (Nasdaq: TRVN) announced the advancement of TRV045, a novel S1P1 receptor modulator, into clinical development for diabetic neuropathic pain (DNP) following FDA approval. Enrollment for a three-part Phase 1 trial will start in early Q1 2022, focusing on safety, tolerability, and pharmacokinetics in healthy volunteers. DNP affects over 5 million people in the U.S., with current therapies facing efficacy and tolerability issues. TRV045 aims to provide a new treatment approach. Collaboration with NIH also explores its use for epilepsy.
Trevena, Inc. (Nasdaq: TRVN) announced a commercial launch of OLINVYK with an expanded medical team targeting key decision-makers. The company initiated a new cognitive function study comparing OLINVYK and IV morphine, with enrollment starting in Q1 2022. Ongoing studies include evaluations of OLINVYK's effects on respiratory and gastrointestinal functions. Despite a net loss of $13.9M in Q3 2021, Trevena reported $78.6M in cash, projected to support operations through 2022. A conference call is scheduled for November 15, 2021, to discuss results and updates.
Trevena, Inc. (Nasdaq: TRVN) has appointed Patricia Drake as the new Chief Commercial Officer, effective immediately. With over 30 years of experience, Drake aims to enhance the market presence of OLINVYK, Trevena's opioid analgesic approved by the FDA in August 2020. Under her guidance, the company plans to accelerate formulary wins and optimize its sales strategy. Bob Yoder also assumes the role of Chief Business Officer, working with Drake to bolster OLINVYK's launch and advance the company's clinical pipeline, particularly focusing on TRV027 for various indications.
Trevena, Inc. (Nasdaq: TRVN) reported it will release its third-quarter financial results for 2021 on November 15, at 8:00 a.m. ET. The announcement includes a conference call that will feature management and insights from Paul F. Rider, M.D. about the use of OLINVYK in colorectal surgery. The company continues to focus on CNS disorders and has one approved product, OLINVYK, along with several investigational drug candidates targeting various medical conditions.
Trevena, Inc. (TRVN) announced two presentations at the ANESTHESIOLOGY 2021 conference, focusing on safety data from the OLINVYK (oliceridine) injection program. The studies demonstrated that obese patients and those with moderate to severe renal impairment are not at an increased risk for opioid-related adverse events (ORAEs). The OLINVYK program aims to provide valuable information for post-operative care. OLINVYK is a FDA-approved analgesic for acute pain management, addressing a significant medical need.
Trevena, Inc. (Nasdaq: TRVN) announced promising results from its proof-of-concept study of TRV027 in hospitalized COVID-19 patients. The data showed a 92% probability of TRV027's beneficial impact on D-dimer levels, a key biomarker for critical illness. Patients treated with TRV027 experienced a 12-day lower average hospital stay compared to placebo. The study included 30 patients, with 70% of those treated showing reduced D-dimer levels. TRV027 is being evaluated in larger ongoing studies (ACTIV-4 and REMAP-CAP), with data expected in mid-2022.
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on CNS disorders, will present at the Oppenheimer 2021 Fall Healthcare Life Sciences & MedTech Summit from September 20-23, 2021. Carrie Bourdow, President and CEO, will deliver the presentation on September 21 at 8:15 a.m. ET. A webcast link is available on the company’s website, with the replay accessible for 30 days post-event. Trevena's pipeline includes investigational drugs TRV250, TRV734, TRV045, and TRV027, aimed at various CNS conditions and COVID-19 complications.
Imvax announced the appointment of John M. Limongelli as the Chief Legal Officer effective September 16, 2021. Limongelli brings nearly 25 years of experience in the biopharma industry, having previously held significant roles at Neos Therapeutics and Trevena, Inc. (NASDAQ: TRVN). His expertise is expected to enhance Imvax's leadership as the company focuses on expanding its immunotherapy platform for solid tumors, with IGV-001 aimed at treating glioblastoma. CEO John Furey highlighted Limongelli's potential contributions to the company's growth.
On September 9, 2021, Trevena (Nasdaq: TRVN) announced that Carrie Bourdow, its President and CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will occur on September 13 at 7:00 a.m. ET.
A webcast link will be available on the company’s Investors page, and a replay will be accessible for 30 days post-event. Trevena is focused on CNS disorders and has one approved product, OLINVYK®, along with a pipeline of investigational drug candidates.
Trevena, Inc. (Nasdaq: TRVN) announced the acceptance of two abstracts at ANESTHESIOLOGY® 2021, focusing on the safety data from the OLINVYK (oliceridine) injection program. The conference, held from October 8 to 12 in San Diego, will feature a top research abstract and highlights from two e-posters. OLINVYK is FDA-approved for managing acute pain in adults requiring intravenous opioid analgesics. The company continues to emphasize the medical community's interest in OLINVYK's profile.
FAQ
What is the current stock price of TREVENA (TRVN)?
What is the market cap of TREVENA (TRVN)?
What is Trevena, Inc.?
What is OLINVYK®?
What recent developments has Trevena announced?
What is TRV045?
How is Trevena's financial performance?
What types of products does Trevena develop?
Are Trevena's products FDA approved?
What partnerships does Trevena have?
Where can I find more information about Trevena’s research?
What are the primary focus areas of Trevena's research?
